Compare Adaptive Biotechnologies Corp (ADPT) vs Ford Motor Company (F) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Ford Motor Company — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while Ford Motor Company trades at $13.85 (market cap $55.75B). The key difference: Ford Motor Company is far larger — about 13.8× Adaptive Biotechnologies Corp's market cap, and Ford Motor Company pays a 4.29% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | F | |
|---|---|---|
Market Cap | $4.04B | $55.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $25.45 | $17.44 |
52-Week Low | $12.30 | $11.21 |
Enterprise Value | $4.10B | $187.71B |
Dividend Yield | — | 4.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
Ford Motor Company (F) trades at $13.865, down 1.07% on the day, with a bearish technical signal. Recent earnings show volatility, with Q2 2026 beating expectations but Q4 2025 missing. The company reported a net loss of $8.18B in 2025 despite $187.27B revenue, though operating cash flow remains strong at $21.28B. News highlights the upcoming Fathom EV truck priced at $28,350, targeting affordability in 2027.
The outlook is mixed; low P/E of 11.84 and analyst consensus price target of $16.18 suggest potential upside, but negative net income margin and high debt pose risks. Investor sentiment is cautious amid EV transition costs and competitive pressures, with 38.3% of analysts rating Buy. Key opportunities include new affordable models and strong cash flow, while execution on profitability remains critical.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Ford Motor Company
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →
